Aldeyra Therapeutics, Inc. (ALDX) Raised Price Target to $9, Analyst Says.
ByAinvest
Saturday, Aug 23, 2025 4:25 am ET1min read
ALDX--
Aldeyra Therapeutics, Inc. (ALDX) has had its price target raised to $9 by JonesTrading, a potential upside of 66.98% from the current price. The FDA has accepted the company's NDA resubmission for its lead product, Reproxalap, aimed at dry eye disease. AbbVie is expected to pay $100 million upfront and share US profits if approved. The company's platform includes follow-on assets like ADX-629 and ADX-2191.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet